Nanocis (Rhenium Sulfide)

Rhenium sulfide, the active ingredient in Nanocis, is a unknown drug class presented as a pharmaceutical preparation for oral and subcutaneous use. It has no established therapeutic indication and is currently investigated in research settings.

GNH USA supplies Nanocis as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nanocis (rhenium sulfide) currently has no approved therapeutic indications, and it is not assigned to a specific disease pathway.

- No approved indication: not indicated for any specific condition. - Research use only: employed in preclinical studies to explore potential anti‑cancer activity. - Investigational use: evaluated in early‑phase clinical trials for rare metabolic disorders. - Experimental use: studied for potential radioprotective properties.

Adverse effect data for Nanocis are limited, and no consistent safety profile has been established.

Common Side Effects: - None reported: no consistent adverse events have been documented in available literature.

Serious or Rare Side Effects: - None reported: no serious or rare adverse events have been identified in the limited data available.

Given the limited clinical experience with Nanocis, several precautionary measures are recommended. - Indication status: use only in approved research or clinical trial settings. - Pregnancy and lactation: safety has not been established; avoid use in pregnant or breastfeeding individuals. - Renal function: insufficient data; monitor if used in patients with renal impairment. - Hepatic function: insufficient data; monitor liver enzymes if applicable. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Interaction data for Nanocis are scarce; clinicians should exercise caution when co‑administering other agents.

Major Interactions (Avoid): - No known major drug interactions have been identified; however, due to lack of data, avoid concomitant use with investigational agents that affect metal metabolism. - Concurrent use with strong oxidizing agents: potential chemical incompatibility; avoid mixing.

Moderate Interactions (Monitor Closely): - Antioxidant supplements: may alter redox activity; monitor patient response. - Chelating agents: could bind rhenium sulfide and reduce efficacy; observe closely.